Kazia Therapeutics (NASDAQ:KZIA) Stock Price Up 5.2%

Kazia Therapeutics Limited (NASDAQ:KZIA)’s share price rose 5.2% during trading on Tuesday . The stock traded as high as $0.30 and last traded at $0.29. Approximately 244,122 shares were traded during trading, a decline of 65% from the average daily volume of 690,750 shares. The stock had previously closed at $0.28.

Kazia Therapeutics Trading Up 5.2 %

The stock’s fifty day moving average price is $0.30 and its 200 day moving average price is $0.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Kazia Therapeutics stock. Platinum Investment Management Ltd. acquired a new position in Kazia Therapeutics Limited (NASDAQ:KZIA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,821,887 shares of the company’s stock, valued at approximately $801,000. Platinum Investment Management Ltd. owned about 11.15% of Kazia Therapeutics as of its most recent SEC filing. 30.89% of the stock is owned by hedge funds and other institutional investors.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.